At IGA, we’re committed to providing exceptional digestive healthcare while helping advance the future of gastrointestinal medicine.
Through our clinical research program, we participate in studies designed to explore new approaches to screening, diagnosis, and treatment. These studies help researchers better understand digestive diseases and evaluate innovative technologies that may improve patient care.
By participating in clinical research, eligible patients have the opportunity to contribute to medical advancements that could benefit future generations.
IGA is participating in a clinical research study sponsored by Natera to evaluate an investigational blood-based screening test for colorectal cancer.
Colorectal cancer screening plays an important role in early detection and prevention. This research aims to evaluate how well a blood test can identify advanced precancerous lesions and other findings when compared with traditional colonoscopy.
Eligible participants will:
The blood sample consists of approximately 9 tubes, totaling 30–90 mL, and must be collected within 120 days before beginning bowel preparation. Participation does not replace your colonoscopy or change the importance of recommended colorectal cancer screening.
You may be eligible to participate if you:
Certain medical conditions, previous cancer diagnoses, or prior colonoscopy findings may affect eligibility. Our research team will review the complete participation requirements with interested patients.
Will Participants Be Compensated?
Eligible participants may receive up to $350 in compensation for their time and study-related costs. Compensation is subject to the study’s participation requirements.
Interested in Participating?
Clinical research provides an opportunity to play a role in advancing digestive healthcare. If you are interested in learning more about our current colorectal cancer screening study, our research team can help determine whether you may qualify.
Contact us to learn more about participating in this research: [email protected]
Participation is voluntary and subject to eligibility requirements. The Natera colorectal cancer screening test is being evaluated as part of a clinical research study and is not intended to replace your recommended screening colonoscopy.
If your insurance requires a referral or prior authorization, our billing office will make every effort to obtain it before services are rendered. If you choose to proceed without required authorization, insurance may deny coverage. If you are a Medicare patient, you may be asked to sign an Advanced Beneficiary Notice (ABN) acknowledging financial responsibility if insurance does not pay. If you are enrolled in a commercial insurance plan you will be asked to sign a non-covered services form.